These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34428542)

  • 41. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
    Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
    Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma.
    Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T
    J Surg Res; 2012 Jan; 172(1):95-101. PubMed ID: 20851413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
    Chan HL; Leung NW; Hui AY; Wong VW; Liew CT; Chim AM; Chan FK; Hung LC; Lee YT; Tam JS; Lam CW; Sung JJ
    Ann Intern Med; 2005 Feb; 142(4):240-50. PubMed ID: 15710957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy.
    Lawitz E; Godofsky E; Rouzier R; Marbury T; Nguyen T; Ke J; Huang M; Praestgaard J; Serra D; Evans TG
    Antiviral Res; 2011 Mar; 89(3):238-45. PubMed ID: 21255610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
    Pereda R; González D; Rivero HB; Rivero JC; Pérez A; López LDR; Mezquia N; Venegas R; Betancourt JR; Domínguez RE
    J Interferon Cytokine Res; 2020 Sep; 40(9):438-442. PubMed ID: 32960147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
    J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].
    Hou FQ; Yin YL; Zeng LY; Shang J; Gong GZ; Pan C; Zhang MX; Yin CB; Xie Q; Peng YZ; Chen SJ; Mao Q; Chen YP; Mao QG; Zhang DZ; Han T; Wang MR; Zhao W; Liu JJ; Han Y; Zhao LF; Luo GH; Zhang JM; Peng J; Tan DM; Li ZW; Tang H; Wang H; Zhang YX; Li J; Zhang LL; Chen L; Jia JD; Chen CW; Zhen Z; Li BS; Niu JQ; Meng QH; Yuan H; Sun YT; Li SC; Sheng JF; Cheng J; Sun L; Wang GQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):589-596. PubMed ID: 29056008
    [No Abstract]   [Full Text] [Related]  

  • 49. [
    Loginova SY; Shсhukina VN; Savenko SV; Borisevich SV
    Vopr Virusol; 2021 May; 66(2):123-128. PubMed ID: 33993682
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C.
    Okuse C; Adachi K; Katakura Y; Matsunaga K; Ishii T; Matsumoto N; Yotsuyanagi H; Iino S; Suzuki M; Itoh F
    J Gastroenterol; 2006 Dec; 41(12):1231-6. PubMed ID: 17287904
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.
    Liu WD; Feng PH; Cheng CY; Chou CL; Lee CH; Lu MC; Liu PY; Lee MH; Liao CH; Chen MC; Chen CP; Hsu SF; Tzeng YT; Lin YC; Ou TY; Qin A; Tsai CY; Shih WJ; Lee KY; Sheng WH
    Infect Dis Ther; 2024 Jul; 13(7):1575-1588. PubMed ID: 38771550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
    Flink HJ; Hansen BE; Heathcote EJ; Feinman SV; Simsek H; Karayalcin S; Mach T; Leemans WF; de Man RA; Verhey E; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Nov; 101(11):2523-9. PubMed ID: 17029610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.
    Cooper C; Shafran S; Greenbloom S; Enns R; Farley J; Hilzenrat N; Williams K; Elkashab M; Abadir N; Neuman M
    Can J Gastroenterol Hepatol; 2014 Jan; 28(1):35-40. PubMed ID: 24212915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.
    Vyas K; Brassard DL; DeLorenzo MM; Sun Y; Grace MJ; Borden EC; Leaman DW
    J Immunother; 2003; 26(3):202-11. PubMed ID: 12806274
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo.
    Yano H; Ogasawara S; Momosaki S; Akiba J; Kojiro S; Fukahori S; Ishizaki H; Kuratomi K; Basaki Y; Oie S; Kuwano M; Kojiro M
    Liver Int; 2006 Oct; 26(8):964-75. PubMed ID: 16953837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients.
    Brockmeyer NH; Poffhoff A; Bader A; Hochdorfer B; Schlottmann R; Rasokat H; Altmeyer P; Kreuter A
    Eur J Med Res; 2006 Jan; 11(1):27-32. PubMed ID: 16504957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.
    Kogure T; Ueno Y; Fukushima K; Nagasaki F; Kondo Y; Inoue J; Matsuda Y; Kakazu E; Yamamoto T; Onodera H; Miyazaki Y; Okamoto H; Akahane T; Kobayashi T; Mano Y; Iwasaki T; Ishii M; Shimosegawa T
    World J Gastroenterol; 2008 Dec; 14(47):7225-4230. PubMed ID: 19084938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.